AbGenomics International Announces The Issuance By The USPTO Of A Patent Covering Its Antibody Drug Conjugate (ADC) Platform

LOS ALTOS, Calif., July 28, 2015 /PRNewswire-iReach/ -- AbGenomics International, Inc. announced today that the United States Patent and Trademark Office (USPTO) issued US Patent No. 9,089,614 entitled "Hydrophilic self-immolative linkers and conjugates thereof". The claims of this patent cover the structures and the use of novel hydrophilic self-immolative linker.

Photo - http://photos.prnewswire.com/prnh/20150721/238975

"Our company is committed to protecting our intangible assets that will lead and have led to ongoing development of therapeutic products and companion diagnostics. This issued patent '614 related to the Company's ADC platform sets a big step for sustaining our strong competitive strength in the field of ADC." said Dr. Ron Lin, Chairman and CEO of AbGenomics. By applying the proprietary linker-payload technology together with site-specific conjugation, AbGenomics has built a strong ADC pipeline for cancer therapy. Those ADC candidates equipped with AbGenomics' ADC platform demonstrated superior in vivo antitumor efficacy and satisfactory safety profile in non-human primates. A proof of safety/efficacy study in cancer patients with one of our ADCs will be initiated in early next year.

About AbGenomics' ADC

ADC is one of the most efficacious agents known for cancer therapy. Many ADCs failed in clinical studies, however, due to toxicity issues. AbGenomics' ADC platform has two significant features: (1) a proprietary stable linker design joined with a powerful payload leads to ADCs with higher potency and lower toxicity; (2) site-specific conjugation at carefully selected conjugation sites further enhances the stability and safety of the ADC. As a result, a significant improvement of the therapeutic index of an ADC is achieved. For more information on AbGenomics' bio-superior/bio-better ADCs, please visit www.abgenomics.com.

Note on Forward-Looking Statements

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.


News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE AbGenomics International Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news